The FDA signed its rejection of ivonescimab on 13 November and put the letter online five days later. Summit’s announcement gave one reason. The letter gives four, and the first is about where the patients were enrolled.
The ivonescimab complete response letter has twelve numbered items, and the first one turns on a fraction. HARMONi, the trial behind the application, was called positive on 275 progression events. The FDA counted 257 of them in patients enrolled in China.
Summit Therapeutics announced the rejection on Sunday 15 November. Its release gave a single reason: overall survival had not reached statistical significance. That is accurate, and it is the letter’s second point. The first point, the geography, is not in the release, and neither is the remedy the FDA wrote down.
Both documents are public now. So are the trial registry and Summit’s own slides, and between them they show how a global trial ended up with 93% of its events in one country.
01The ivonescimab complete response letter lists four deficiencies
The letter is dated 13 November 2026, a day before the review deadline, and its signature is time-stamped 2:08 pm. Summit told the market two days later, so 15 November is the date many readers will have seen. We follow the letter. The FDA’s public record of it was updated on 18 November, and that is how the full text came out.
In the agency’s order, the four clinical deficiencies are these.
- The PFS result cannot be assumed to hold for American patients, because 257 of the 275 events came from China.
- The gain in median PFS was modest, the final survival analysis was not significant, and response rates were not much different.
- The longer follow-up Summit submitted is exploratory, and its survival figures compare regions at different cut-off dates.
- The PFS gain does not outweigh the added toxicity of ivonescimab on top of chemotherapy.
Items five to twelve are the standard request for a safety update. Unlike the letter that stopped Unicycive’s OLC, this one has no manufacturing content at all. That fits what Akeso’s chief executive, Michelle Xia, told investors on 15 November: the trial sites and the Guangzhou plant had passed FDA inspection.
Summit had warned about survival. Its third-quarter release in early November said the FDA had noted that “a statistically significant OS benefit is necessary to support marketing authorization” in this setting. The enrolment objection is a separate matter. The letter says the agency raised it at a Type A meeting in March 2023. It repeated the point in May 2025 at the pre-BLA meeting, the one held before filing. Summit’s 15 November release mentions neither meeting.
02257 of 275: where the events came from
A progression-free survival result is counted in events: a scan that shows growth, or a death. HARMONi’s primary PFS analysis had 275. Ivonescimab plus chemotherapy cut the risk of progression or death by 48%, a hazard ratio of 0.52, and lifted median PFS from 4.4 months to 6.8.
The letter attributes 257 of those events to China. The rest is subtraction.
Events in China 257 (FDA letter)
275 − 257 = 18 events in North America and Europe
18 / 275 = 6.5% of events
Western patients 165 / 438 = 37.7% of those randomised
Summit’s slides show why. The primary PFS analysis did not include all 438 patients. It included 345. All 273 Asian patients had been randomised by November 2022, six months before the first Western site opened, so every one of them is inside the 345. That leaves 72 places for Western patients, fewer than half of the 165 who eventually enrolled.
By the time the trial was called positive, more than nine in ten patients in the Asian cohort had progressed or died. Three in four of the Western patients in the analysis had not yet had an event.
The letter puts China at 60% of the study population. Summit’s slides give 273 of 438, or 62.3%. Our arithmetic uses the slide counts.
Summit later ran the analysis with all 438 patients. It gave a hazard ratio of 0.57 overall, 0.55 in Asia and 0.67 in North America and Europe, where the upper end of the interval sits at 1.00. The FDA classes that follow-up as exploratory.
03Two registry records, 464 days apart
ClinicalTrials.gov shows how HARMONi was put together, because it is two records. Chinese patients went in under NCT05184712, an Akeso trial that started on 25 January 2022 and enrolled 322 people. Summit sponsors the global record, NCT06396065, which starts on 4 May 2023.
That global record lists 74 sites in six countries. Forty-three are in the United States, 13 in Spain, six in Canada, five each in France and Italy and two in the United Kingdom. None is in China or anywhere else in Asia, where 273 of the 438 patients were enrolled.
In regulatory language, the letter describes the same thing: a study designed for China alone and widened afterwards. Its dates, with those from the registry and Summit’s slides, give this sequence.
Look at the order. The FDA put its concern about enrolment on record in March 2023. Western enrolment began two months later. In May 2025 the agency said it again, and the application arrived that November.
Xia’s account on the Akeso call was that the FDA had agreed to the sequential design while saying from the start that survival would have to be significant. She called it “the most disappointing moment” for her personally in Akeso’s 14 years. Her account and the letter do not contradict each other. A regulator can allow a trial to run and still say what it will not prove.
04The survival update runs on two clocks
Overall survival was HARMONi’s other primary endpoint, and it missed. At the April 2025 analysis the hazard ratio was 0.79, with a 95% interval of 0.62 to 1.01 and a p-value of 0.057. Median survival was 16.8 months with ivonescimab and 14.0 without, a gap of 2.8 months.
Summit kept following the Western patients and reported twice more. By June 2026 the hazard ratio was 0.76, and the interval, 0.61 to 0.95, no longer reached 1. Summit presented that figure in September as evidence of a consistent survival benefit.
The FDA’s third deficiency is about how that figure is assembled. Chinese sites closed during 2025, so follow-up of the Asian patients stops at April 2025. Western patients were followed to June 2026. So the updated number joins one cohort frozen in time to another that kept moving for 14 more months.
Only the top row was pre-specified, and its interval crosses 1. The two Western-only estimates, the ones closest to an American patient, cross it as well: 0.53 to 1.32 in September 2025 and 0.52 to 1.10 in June 2026.
052.4 months gained, 1.85 times the serious adverse events
The fourth deficiency is a judgement, and the letter makes it in a sentence: the PFS gain does not outweigh the risk. It names serious immune-related toxicity and toxicity from VEGF inhibition, and gives no rates. The rates are on Summit’s September 2025 safety slide, with 218 patients in each arm.
Treatment-related adverse events: ivonescimab plus chemotherapy vs chemotherapy
Summit’s release quotes the bottom two rows, where the arms look alike. Xia cited the same two when she said the FDA had recognised the safety profile. The letter rests on the rows above them. Serious treatment-related events reached 61 patients on ivonescimab and 33 on chemotherapy alone, a ratio of 1.85.
On the other side of the scale is the benefit: 2.4 more months of median PFS, and a survival difference that did not pass its test. The FDA drew a similar line between a clinical signal and proof when it turned down Replimune’s RP1.
06What the FDA asked for, and what it left open
The recommendation is short. Run a new, adequate and well-controlled multiregional trial, in line with ICH E17 and the agency’s September 2024 draft guidance on oncology programmes run across regions. Meet the FDA before it starts.
The first analyst notes were written on Sunday night from Summit’s summary. BMO Capital Markets concluded that survival matters most and PFS is “a nice to have”, BioSpace reported. The letter, published three days later, is less absolute. It asks for a statistically significant and clinically meaningful gain in “overall survival, progression-free survival or another endpoint that measures clinical benefit”, large enough to outweigh the toxicity.
So PFS is still on the list. The PFS in this application was 2.4 months wide, 93% Chinese by events, and came with more serious side effects.
There is a precedent, and it was stricter. In February 2022 the FDA’s advisers voted 14 to 1 that sintilimab, a PD-1 antibody tested only in China, needed more evidence. The letter that followed asked for a multiregional trial with overall survival as its endpoint, according to Lilly. The ivonescimab complete response letter does not narrow the endpoint that way.
Europe has just read the sintilimab data differently. On 15 November, the day Summit announced its letter, Innovent said the European Medicines Agency’s CHMP committee had recommended approval on ORIENT-11, the China-only study the FDA declined. Europe is Summit’s territory for ivonescimab. Its third-quarter release mentions no European filing.
07Five positive trials, 7.9% of the patients outside China
Summit’s chairman, Robert Duggan, answered the letter by pointing to five positive Phase 3 studies between Summit and Akeso. The registry lists 18 Phase 3 or Phase 2/3 trials of ivonescimab. Five have stopped recruiting and reported a positive result, and four of those are Akeso trials run in China.
Count each patient once and the five results rest on 2,099 people. Of those, 165 were enrolled outside China, and every one of them is in HARMONi.
HARMONi-3 is the first trial that changes the ratio. It was registered as a multiregional study in October 2023, against Keytruda plus chemotherapy in first-line lung cancer. Its record lists 260 sites in 17 countries: 76 in the United States, 46 in China, and the rest across Europe, Japan, Mexico, Turkey and Canada. China’s share of sites is 17.7% (computed). Enrolment is complete in both cohorts, 600 squamous and 1,000 non-squamous patients on the registry’s numbers.
08$2.63 billion in cash, and a partner 35.6% below its entry price
Summit can afford a second attempt. It ended September with $629.8 million in cash and investments, and AstraZeneca’s $2.0 billion equity investment closed on 5 October.
AstraZeneca equity, closed 5 Oct 2026 $2,000.0M (reported)
Pro forma = $2,629.8M before fourth-quarter spending
Operating cash used, nine months $423.2M (reported) = $141.1M a quarter
That run-rate flatters, because spending is climbing. Non-GAAP operating expenses were $166.9 million in the third quarter, up from $103.4 million a year earlier.
AstraZeneca’s position is the uncomfortable one. Its preferred shares convert at $18.36. Summit closed at $11.82 on Monday 16 November, down 16.4% on the day, and Fierce Pharma reported a further fall of about 10% on Tuesday.
Other large companies have money in the class too. Six licences and acquisitions, every one for a molecule discovered in China, carry $7.29 billion in upfront and guaranteed payments (computed). AstraZeneca’s equity brings the total to $9.29 billion. We traced the pattern behind those deals in The China Biotech Pipeline Grab.
The best-funded rival has not copied HARMONi’s design. BMS and BioNTech sponsor seven Phase 3 or Phase 2/3 trials of pumitamig on the registry. They plan 6,039 patients, and each lists between 161 and 366 sites. Their earliest primary completion date is January 2029.
So the letter’s first deficiency, aimed at a trial assembled in two halves, lands on Summit more than on the class. Its fourth, on toxicity, is a question every PD-1 and VEGF combination will face.
09India: twice the EGFR rate, and no site on the list
EGFR-mutant disease, the setting the FDA turned down, is a larger part of lung cancer in India than in the West. A pooled series of 3,436 Indian lung adenocarcinomas from four tertiary hospitals found EGFR mutations in 30.0% (Nakra et al., 2020, via PubMed). Tata Memorial’s 907-patient study cites 10–15% for North American and European patients (Chougule et al., 2013). On those figures the Indian rate is two to three times the Western one (computed).
Ivonescimab has no route to those patients today. India falls in Akeso’s licence territory. A drug review in the Indian Journal of Medical and Paediatric Oncology recorded no approval from the Drugs Controller General in June 2025. We found no later filing.
The short cut would have been Rule 101. In August 2024 India’s regulator named six jurisdictions whose approvals let it consider waiving a local trial. They are the United States, the United Kingdom, Japan, Australia, Canada and the European Union. The waiver is discretionary and covers five categories of drug. China is not on the list, so the approval ivonescimab has held there since May 2024 opens nothing in India. The United States is the first of the six where a decision is known, and the decision was no.
The site lists tell the same story from the other end. HARMONi names 74 sites and HARMONi-3 names 260. None is in India. If Summit runs the multiregional trial the FDA has described, it will need EGFR-mutant patients outside China. Indian hospitals see that mutation at no less than twice the Western rate. We made the wider case in India’s next CRO boom.
10Witfire Risk Score: 6.0 / 10
The score covers Summit’s ivonescimab franchise in the United States after the letter.
11What to watch
- By 31 December 2026. Summit expects the primary PFS analysis for HARMONi-3’s squamous cohort in the fourth quarter, with an early look at survival. Read the regional split of events before the hazard ratio. SMMT closed at $11.82 on 16 November against AstraZeneca’s $18.36, and Akeso (9926.HK) closed at HK$64.10.
- Summit’s investor call. The company said in early November it would hold one after the FDA acted. It had not by 17 November, Fierce Pharma reported. Citi says Summit is weighing a resubmission, and the letter asks for a new trial. Which of the two management describes will show how it has read the letter.
- First half of 2027. A survival interim for the squamous cohort that does not depend on PFS, and the PFS events for the non-squamous cohort.
- 13 November 2027. The one-year limit to resubmit or ask for an extension under 21 CFR 601.3(b), computed from the letter date. A Type A meeting request would be the first public sign of a plan.
- January 2029. The earliest primary completion date among the pumitamig trials: BioNTech’s first-line lung cancer protocol, 1,580 patients at 366 sites (BNTX, BMY).
The letter is narrower than Sunday’s headlines and harder than Summit’s release. PFS remains an endpoint the FDA will accept. What it turned down was a PFS result that came 93% from China, measured 2.4 months, and carried nearly twice the rate of serious adverse events.
Summit’s deeper exposure is in the patient count. Across the five trials it calls positive, 7.9% of patients were enrolled outside China, and all of them are in HARMONi. HARMONi-3 is the first data set that can move that number, and its squamous cohort reports before the year ends.
The ivonescimab complete response letter has put a first American label out of reach for now. Summit has $2.63 billion to spend on a reply, and the regulator has now put in writing what the reply needs to show.
FAQIvonescimab and the FDA: five questions
Why did the FDA reject ivonescimab?
The ivonescimab complete response letter, dated 13 November 2026, lists four clinical deficiencies. First, 257 of the 275 progression-free survival events in the HARMONi trial came from patients enrolled in China, so the result could not be applied to US patients. Second, the PFS gain was modest and overall survival was not statistically significant (hazard ratio 0.79, p = 0.057). Third, the later follow-up analyses were exploratory. Fourth, the benefit did not outweigh the added toxicity.
What does the ivonescimab complete response letter ask Summit to do?
It recommends a new, adequate and well-controlled multiregional trial consistent with ICH E17. The trial must show a statistically significant and clinically meaningful improvement in overall survival, progression-free survival or another clinical benefit endpoint, large enough to outweigh the toxicity. Summit has one year from 13 November 2026 to resubmit or ask for an extension.
Does the FDA now require overall survival for PD-1/VEGF bispecifics?
The published letter does not say so. It names overall survival, progression-free survival or another clinical benefit endpoint as acceptable for a new trial. Summit has separately reported that the FDA said a statistically significant survival benefit was necessary in the HARMONi setting.
When is the next ivonescimab readout?
Summit expects the primary PFS analysis for the squamous cohort of HARMONi-3, with an early interim look at survival, in the fourth quarter of 2026. A separate survival interim and the non-squamous PFS analysis are planned for the first half of 2027.
Is ivonescimab approved in India?
No Indian approval has been recorded. India is in Akeso’s licence territory. India’s Rule 101 waiver list covers approvals from the US, UK, Japan, Australia, Canada and the EU. It does not include China, where ivonescimab has been approved since May 2024.
Disclosure: Editorial analysis, not investment or medical advice. The Witfire Risk Score is our own framework, weighting Regulatory Exposure (30%), Competitive Displacement (25%), Capital Position (20%), Evidence Integrity (15%) and Execution & Credibility (10%) on a 1–10 scale. Scores are judgments, not forecasts.
Put this framework on your own file.
The same method used in these briefs, applied privately to a decision you are actually facing — a target, a partner, a facility, a filing.
- CMC & manufacturing risk assessment
- Regulatory / CRL readiness review
- Due diligence on a target or partner
- Investor brief or market analysis
- Commissioned editorial
- Something else
The signal before the market catches up.
A low-noise briefing on the pharma events that change strategy, risk and value. No more than one a week.
